Orthocell shares up 10% today; anticipates FDA approval in the coming weeks

Some big news could be just days away for this growing regenerative medicine company.

| More on:
Shot of a young scientist using a digital tablet while working in a lab.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Orthocell Ltd (ASX: OCC) share price is catching the eye of investors on Monday.

In late afternoon trade, the regenerative medicine company's shares are up over 10% to $1.37.

This means that Orthocell shares are now up approximately 250% since this time last year.

What is Orthocell?

Orthocell is a regenerative medicine company with a focus on regenerating mobility for patients by developing products for the repair of a variety of bone and soft tissue injuries.

Its portfolio includes the CelGro platform of collagen medical devices which facilitate tissue reconstruction and healing in a variety of dental and orthopaedic reconstructive applications.

Striate+ was the first product approved for dental GBR applications, and is distributed globally by BioHorizons Implant Systems Inc. It is cleared for use in the US, Canada, Australia, New Zealand, the UK, and Europe.

SmrtGraft is for tendon repair and is available in Australia under Special Access Scheme or participation in a clinical trial.

Finally, there is the very promising Remplir product, which is used for peripheral nerve reconstruction. It recently received approval in Australia, New Zealand and Singapore and is distributed exclusively by Device Technologies.

It is Remplir that has been getting investors excited recently and could explain why Orthocell shares are charging higher today.

The company recently noted that it remains on track to gain US FDA 510(k) regulatory clearance to commercially distribute Remplir into the critical US$1.6 billion US market. It is expecting approval from the regulator in late March or early April 2025. This means that it could be just weeks (or even days) away from being received.

This would be great news as management notes that Remplir has gained excellent sales traction since its Australian market launch in November 2022.

In fact, it has achieved three consecutive quarters of record revenue. There are now ~180 orthopaedic and plastic surgeons now using Remplir in peripheral nerve repair surgeries across Australia, New Zealand and Singapore.

What else is boosting Orthocell shares?

Also potentially giving the Orthocell share price a boost is its addition in the All Ordinaries index.

The company will be officially added to the index next Monday following the quarterly rebalance

This could have opened up the company to fund managers that have strict investment mandates preventing them from investing in companies outside the index. It could also mean that funds tracking the index are buying shares ahead of its inclusion.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended Orthocell. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

a young woman holds her hand to her ear and leans sideways as if to listen to something that's surprising her as her eyes and her mouth are wide open.
Healthcare Shares

Down 15% since January, are Cochlear shares now a buy?

Let's see what analysts are saying about this blue chip.

Read more »

Green arrow with green stock prices symbolising a rising share price.
Healthcare Shares

Guess which popular ASX 200 stock is up nearly 60% in less than 2 months?

Investors who bought this ASX 200 stock in the recent dip have been strongly rewarded.

Read more »

A senior pharmacist talks to a customer at the counter in a shop.
Healthcare Shares

Are Sigma Healthcare shares a good buy now after the merger with Chemist Warehouse?

Sigma Healthcare shares have soared 154% in 12 months. Can this stellar run continue?

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

Up 34% since April, ASX 300 healthcare stock lifts off again today on new milestone

The ASX 300 healthcare stock has been on a tear since hitting one-year lows in April.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

Should I buy the dip on CSL shares?

A leading fund manager gives his verdict on the growth prospects for CSL shares.

Read more »

A woman relaxes on a yellow couch with a book and cuppa, and looks pensively away as she contemplates the joy of earning passive income.
Healthcare Shares

NIB shares have soared 24% this year. Does Macquarie expect this to continue?

Will this private health insurer continue to deliver big returns? Let's find out.

Read more »

Woman presenting financial report on large screen in conference room.
Healthcare Shares

Up nearly 30% in a year, should I buy Fisher & Paykel shares before its earnings result?

Will the ASX 200 healthcare stock continue to outperform?

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

CSL shares among most expensive on ASX. Is now a good time to buy?

Analysts predict CSL share price growth will keep on coming.

Read more »